Immunology of multiple sclerosis

被引：26

作者：

Bar-Or, A

机构：

[1] McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ H3A 2B4, Canada

[2] McGill Univ, Montreal, PQ, Canada

[3] McGill Univ Hosp Ctr, Montreal Neurol Hosp, Montreal, PQ, Canada

来源：

NEUROLOGIC CLINICS | 2005年 / 23卷 / 01期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1016/j.ncl.2004.11.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A model of multiple sclerosis (MS) immunopathophysiology is presented to illustrate the basic principles by which peripheral immune responses interact with the blood-brain barrier and have an impact on the central nervous system compartment. The model also considers the putative targets and modes of action of several MS therapies. Overall, this article should provide useful background for more detailed discussions of therapeutic strategies.

引用

收藏

页码：149 / +

页数：28

相关论文

共 185 条

[51] Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis [J].

Duda, PW ;

Schmied, MC ;

Cook, SL ;

Krieger, JI ;

Hafler, DA .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) :967-976

[52] Distinct profiles of human B cell effector cytokines: A role in immune regulation? [J].

Duddy, ME ;

Alter, A ;

Bar-Or, A .

JOURNAL OF IMMUNOLOGY, 2004, 172 (06) :3422-3427

[53] Autoimmune diseases: genes, bugs and failed regulation [J].

Ermann, J ;

Fathman, CG .

NATURE IMMUNOLOGY, 2001, 2 (09) :759-761

[54] Treatment of multiple sclerosis with Copaxone (COP) Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells [J].

Farina, C ;

Bergh, FT ;

Albrecht, H ;

Meinl, E ;

Yassouridis, A ;

Neuhaus, O ;

Hohlfeld, R .

BRAIN, 2001, 124 :705-719

[55] Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis [J].

Filippi, M ;

Bozzali, M ;

Rovaris, M ;

Gonen, O ;

Kesavadas, C ;

Ghezzi, A ;

Martinelli, V ;

Grossman, RI ;

Scotti, G ;

Comi, G ;

Falini, A .

BRAIN, 2003, 126 :433-437

[56] B cells regulate autoimmunity by provision of IL-10 [J].

Fillatreau, S ;

Sweenie, CH ;

McGeachy, MJ ;

Gray, D ;

Anderton, SM .

NATURE IMMUNOLOGY, 2002, 3 (10) :944-950

[57] Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients [J].

Galboiz, Y ;

Shapiro, S ;

Lahat, N ;

Rawashdeh, H ;

Miller, A .

ANNALS OF NEUROLOGY, 2001, 50 (04) :443-451

[58] Late complications of immune deviation therapy in a nonhuman primate [J].

Genain, CP ;

Abel, K ;

Belmar, N ;

Villinger, F ;

Rosenberg, DP ;

Linington, C ;

Raine, CS ;

Hauser, SL .

SCIENCE, 1996, 274 (5295) :2054-2057

[59] Identification of autoantibodies associated with myelin damage in multiple sclerosis [J].

Genain, CP ;

Cannella, B ;

Hauser, SL ;

Raine, CS .

NATURE MEDICINE, 1999, 5 (02) :170-175

[60] Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy [J].

Genc, K ;

Dona, DL ;

Reder, AT .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) :2664-2671

← 1 2 3 4 5 6 7 8 9 10 →